Published in J Cancer Res Clin Oncol on September 27, 2008
Immunotherapy targets in pediatric cancer. Front Oncol (2012) 0.97
Differential evolution of MAGE genes based on expression pattern and selection pressure. PLoS One (2012) 0.87
Frequent MAGE mutations in human melanoma. PLoS One (2010) 0.87
IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS One (2012) 0.84
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer (2013) 0.82
Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Mod Pathol (2014) 0.77
The expression and clinical significance of melanoma-associated antigen-A1, -A3 and -A11 in glioma. Oncol Lett (2013) 0.75
Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer. Dis Markers (2016) 0.75
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Molecular biology of neuroblastoma. J Clin Oncol (1999) 6.54
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol (1988) 4.35
DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol (1999) 3.76
Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics (1994) 2.93
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A (1996) 2.63
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Epigenetics and human disease: translating basic biology into clinical applications. CMAJ (2006) 1.98
Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol Cell Biol (2004) 1.39
Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr (2003) 1.36
Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res (2001) 1.23
Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun (2003) 1.19
MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res (2004) 1.17
MAGE-1 gene product is a cytoplasmic protein. Int J Cancer (1994) 1.17
The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics (1995) 1.16
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother (2004) 1.15
Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol (2001) 1.03
Genetic instability in human tumors. EXS (2006) 0.96
MAGE-11 protein is highly conserved in higher organisms and located predominantly in the nucleus. Int J Cancer (1998) 0.95
Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer (2007) 0.93
cDNA and protein characterization of human MAGE-10. Int J Cancer (1999) 0.87
Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res (1999) 0.84
MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genet Cytogenet (2003) 0.83
A novel protein-DNA interaction involved with the CpG dinucleotide at -30 upstream is linked to the DNA methylation mediated transcription silencing of the MAGE-A1 gene. Cell Res (2004) 0.81
There is no evidence that the SDHB gene is involved in neuroblastoma development. Oncol Res (2005) 0.80
Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Med Pediatr Oncol (2001) 0.77
Minimal residual disease in neuroblastoma: to GAGE or not to GAGE. Oncol Res (2004) 0.76
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
Molecular analysis of 250 patients with autosomal recessive congenital ichthyosis: evidence for mutation hotspots in ALOXE3 and allelic heterogeneity in ALOX12B. J Invest Dermatol (2009) 2.58
The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. Haematologica (2006) 2.13
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol (2011) 1.62
[Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients]. Enferm Infecc Microbiol Clin (2009) 1.41
Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant (2006) 1.28
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol (2009) 1.27
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol (2010) 1.24
Impact of end-stage renal disease care in planned dialysis start and type of renal replacement therapy--a Spanish multicentre experience. Nephrol Dial Transplant (2006) 1.21
Analysis of patient flow into dialysis: role of education in choice of dialysis modality. Perit Dial Int (2005) 1.16
Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol (2009) 1.13
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol (2010) 1.09
Assessment of heavy metal levels in Almendares River sediments--Havana City, Cuba. Water Res (2005) 1.07
Three-year clinical evaluation of In-Ceram Zirconia posterior FPDs. Int J Prosthodont (2004) 1.04
Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer (2006) 1.03
Evaluation of MLPA for the detection of cryptic subtelomeric rearrangements. J Lab Clin Med (2006) 1.03
miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res (2011) 1.03
Ultrasound guidance for lateral midfemoral sciatic nerve block: a prospective, comparative, randomized study. Anesth Analg (2007) 1.02
Endothelial progenitor cells: a new key for endothelial dysfunction in migraine. Neurology (2012) 0.96
Do needs, symptoms or disability of outpatients with schizophrenia influence family burden? Soc Psychiatry Psychiatr Epidemiol (2008) 0.96
Novel UBE3A mutations causing Angelman syndrome: different parental origin for single nucleotide changes and multiple nucleotide deletions or insertions. Am J Med Genet A (2009) 0.93
Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion. PLoS One (2013) 0.93
Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog (2010) 0.92
MR arthrography of the shoulder using an anterior approach: optimal injection site. AJR Am J Roentgenol (2008) 0.91
Intragenic GNAS deletion involving exon A/B in pseudohypoparathyroidism type 1A resulting in an apparent loss of exon A/B methylation: potential for misdiagnosis of pseudohypoparathyroidism type 1B. J Clin Endocrinol Metab (2009) 0.90
Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer (2011) 0.89
Duplication of 14q11.2 associates with short stature and mild mental retardation: a putative relation with quantitative trait loci. Am J Med Genet A (2007) 0.89
Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor. PLoS One (2013) 0.89
Detection of hypomethylation syndrome among patients with epigenetic alterations at the GNAS locus. J Clin Endocrinol Metab (2012) 0.89
(123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer (2009) 0.87
Enrichment of ultraconserved elements among genomic imbalances causing mental delay and congenital anomalies. BMC Med Genomics (2010) 0.87
Common pathological mutations in PQBP1 induce nonsense-mediated mRNA decay and enhance exclusion of the mutant exon. Hum Mutat (2010) 0.86
Tyrosinemia type 1 and Angelman syndrome due to paternal uniparental isodisomy 15. J Inherit Metab Dis (2009) 0.86
Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol (2002) 0.85
The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn Mol Pathol (2005) 0.85
Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch (2006) 0.84
X-linked infantile spinal muscular atrophy: clinical definition and molecular mapping. Genet Med (2007) 0.84
Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. J Cancer Res Clin Oncol (2011) 0.84
A two base pair deletion in the PQBP1 gene is associated with microphthalmia, microcephaly, and mental retardation. Eur J Hum Genet (2006) 0.83
Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting. J Mol Diagn (2012) 0.83
MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genet Cytogenet (2003) 0.83
Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients. Ann Hematol (2012) 0.82
Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content. Histopathology (2011) 0.82
Robust, easy, and dose-sensitive methylation test for the diagnosis of Prader-Willi and Angelman syndromes. Genet Test (2006) 0.81
Reproducibility of sonographic measurements of the median nerve. J Ultrasound Med (2008) 0.81
Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution Experience. J Pediatr Hematol Oncol (2015) 0.81
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro Oncol (2013) 0.81
Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors. Pediatr Blood Cancer (2009) 0.80
[Multilocular cystic nephroma. A diagnostic and therapeutic challenge. Report of two cases]. Arch Esp Urol (2004) 0.80
Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification. Transl Res (2009) 0.80
Neuroblastoma in adolescents: genetic and clinical characterisation. Clin Transl Oncol (2010) 0.80
There is no evidence that the SDHB gene is involved in neuroblastoma development. Oncol Res (2005) 0.80
Age does not appear to be a major indicator of CDKN2A or CDK4 mutations in melanoma patients in Spain. Melanoma Res (2005) 0.80
Retained intravascular fragments after removal of indwelling central venous catheters: a single institution experience. J Pediatr Surg (2010) 0.80
A comparison of current neuroblastoma chemotherapeutics. Expert Opin Pharmacother (2004) 0.79
Wrist arthrography: a simple method. Eur Radiol (2005) 0.79
An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer. Breast (2013) 0.79
Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. Leuk Res (2010) 0.79
Duplication at Xq13.3-q21.1 with syndromic intellectual disability, a probable role for the ATRX gene. Am J Med Genet A (2014) 0.78
Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clin Transl Oncol (2010) 0.78
Congenital fibrosarcoma simulating congenital hemangioma. Pediatr Dermatol (2008) 0.78
Intronic mutations affecting splicing of MBTPS2 cause ichthyosis follicularis, alopecia and photophobia (IFAP) syndrome. Exp Dermatol (2011) 0.78
Infectious and immunologic phenotype of MECP2 duplication syndrome. J Clin Immunol (2015) 0.78
Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol (2009) 0.78
Microphthalmia with linear skin defects syndrome. Pediatr Dermatol (2012) 0.77
Screening individuals with intellectual disability, autism and Tourette's syndrome for KCNK9 mutations and aberrant DNA methylation within the 8q24 imprinted cluster. Am J Med Genet B Neuropsychiatr Genet (2014) 0.77
Transfer of brachioradialis motor branch to the anterior interosseous nerve in C8-T1 brachial plexus palsy. An anatomic study. Microsurgery (2012) 0.77